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Background: Over the last few years there has been growing interest in use of visual
measures as useful tools for multiple sclerosis (MS) prognosis and tracking. Optic
neuritis (ON) being a prevalent and often-presenting symptom of the disease, as well
as the high occurrence rate of posterior visual system damage independent of ON
(optic radiation lesions), make the visual system a prime candidate for such endeavors.
However, while the visual system makes for a convenient model in early stages of MS,
processes which may be true in those stages may drastically change as the disease
progresses, due to accumulated disease load. Here, we examine whether vision-related
tools reflect demyelinative and axonal damage of the visual pathways and may be used
for assessment in the clinical setup in progressive multiple sclerosis (MS) patients, in
whom disease load may alter the early stage picture.
Methods: Forty-eight progressive MS patients, with and without prior optic neuritis
(ON), underwent a battery of behavioral tests, visual evoked potential (VEP) tests, optical
coherence tomography (OCT), and structural MRI scans, at two time-points. Data
were analyzed for stability between visits and for correlation between behavioral and
electrophysiological data.
Results: All measures were stable between visits. Significant differences were found in
all measures between the affected and fellow eyes of ON patients and in VEP latencies
between the affected and non-ON eyes. Motion perception differentially correlated with
latencies of both ON eyes and with the non-ON eyes. Retinal nerve fiber layer thickness
correlated with the latencies of non-ON eyes but not of either ON eye. No difference in
lesion load was found between the ON and non-ON patients.
Conclusions: ON still leaves its mark in the patient’s visual system over time, with all
visual measures of the affected eyes notably reduced compared to fellow eyes. Motion
perception, reflecting myelination level along the visual pathway, shows its usefulness
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also in progressive MS. In the non-ON eyes, axonal loss appears to explain prolonged
latencies, unlike in ON eyes, where demyelination appears to be the main mechanism.
Lastly, the visual measures assessed herein are applicable as valid assessment tools
in therapeutic studies.
Keywords: optic neuritis, motion perception, OCT, VEP, fellow eye, multiple sclerosis
INTRODUCTION
Over the last few years there has been growing interest
in the use of visual measures as useful tools for multiple
sclerosis (MS) prognosis and tracking. Optic neuritis (ON)
being such a prevalent and often-presenting symptom of the
disease, as well as the high occurrence rate of posterior
visual system damage independent of ON (optic radiation
lesions), make the visual system a prime candidate for
such endeavors (1, 2). Current studies make use of a wide
variety of visual measures, from behavioral tests such as low-
contrast letter acuity (LCLA) (3) and motion perception (4),
through imaging methods such as optical coherence tomography
(OCT) (5–8) and magnetic resonance imaging (MRI) (9,
10), to the electrophysiological visual evoked potential (VEP)
test (11).
However, most previous studies dealing with visual tools
in MS focused on acute cases of ON and early-stage MS,
looking at different aspects of myelin and axonal damage
in the visual system and its predictive value for disease
prognosis. While the visual system, as well-defined as it is,
makes for a convenient model in the early stages of MS,
processes which may be true in those early stages may
drastically change as the disease progresses, due to accumulated
disease load.
In the current study, we seek to examine whether previously
established observations regarding vision and vision-related
measures in clinically isolated acute ON patients hold true in
progressive MS patients in whom disease progression may alter
the picture.
METHODS
Subjects
Forty-eight progressive MS patients, designated MS-ALL, were
enrolled in a longitudinal mesenchymal stem cell therapy study
(NCT02166021), conducted at the Hadassah-Hebrew University
Medical Center from January 2015 to June 2018, comprising
nine visits over the duration of 1 year. Six visits included visual
assessments. The scope of this study is the screening and baseline
assessments, prior to therapeutic intervention, scheduled roughly
2 months apart. Inclusion criteria for the full study were the
2010 revised McDonald criteria for MS (12), age 25–64, disease
duration of at least 3 years, progressive forms of MS, EDSS
score of 3.5–6.5, and failure to respond to the currently-available
registered treatments. Exclusion criteria were treatment with
cytotoxic or immunomodulatory medications in the 3 months
prior to inclusion, significant diseases that may risk the patient or
interfere with results, active infections, severe cognitive decline,
as tested by the Brief International Cognitive Assessment for MS
(BICAMS) (13), and previous cellular treatment of any kind.
For analysis purposes, the MS-ALL group was divided
into two subgroups, based on reported prior history of ON,
designated MS-ON and MS-nON. In the MS-ON subgroup,
affected (AE) and fellow (FE) eyes were defined. Following
initial between-visit stability analysis, bilateral ON patients were
removed from subgroup analyses, since our interest lies in the
difference between ON AEs and FEs and in these subjects effects
cannot be separated.
This study was approved by the Hadassah-Hebrew University
Medical Center Ethics Committee. All participants gave written
informed consent.
Data Acquisition and Analysis
All behavioral, electrophysiological, and imaging measures were
taken at two consecutive time points, ∼2 months apart. All tests
were performed with best-corrected visual acuity for all subjects.
Visual Acuity (VA) and Low-Contrast Letter
Acuity (LCLA)
Visual acuity (VA) and low-contrast letter acuity (LCLA) were
measured using a multi-contrast Sloan letter chart at 100 and
2.5%, respectively. VA results were converted to decimal scale.
LCLA results were converted to a scale of 0–60 using bins of 5 (5
points assigned to each line that could be fully determined).
Color Perception
Color perception was assessed using pseudochromatic plates 5–
10 of the Hardy Rand and Rittler (HRR) color test with a score
of 1 given for full recognition of shapes and 0 for partial or no
recognition, in any given plate.
Motion Perception
Motion perception was assessed using object-from-motion
(OFM) and number-from-motion (NFM) extraction tasks, based
on the opposing movement of dot arrays outside and inside the
formed object/number. The camouflaged object/number cannot
be discerned when the dots are stationary [these tests have been
previously described (14)]. Briefly, stimuli were presented at
seven speeds, the slowest being most difficult. Scoring for each
stimulus correctly identified was according to the relative weight
given to each speed (e.g., 7 points for level 1, 6 for level 2, etc.).
Maximum score was 140.
Visual Evoked Potentials (VEP)
Visual evoked potentials (VEP) were recorded by a trained
technician on a Bravo VEP device (Nicolet Biomedical) using
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standard full-field pattern-reversal VEP parameters. Lateral
electrodes were placed at O1 and O2 with a reference electrode
at Fz and ground electrode at the vertex. Abnormal values were
defined as above 114ms. VEP P100 latencies and amplitudes were
extracted. At least two repetitions were recorded for each eye, the
reported values being an average of the two recordings.
Peripapillary Retinal Nerve Fiber Layer (pRNFL)
Thickness and Macular Volume
Peripapillary retinal nerve fiber layer (pRNFL) thickness and
macular volume were recorded by trained technicians using
spectral-domain OCT (Spectralis, Heidelberg Engineering) with
automatic real time (ART) function for image averaging. pRNFL
was derived from standard ring scans around the optic nerve
head. Macular volume was derived from custom macula scans
(30◦ × 25◦, 61 B-scans, ART: 13 frames). All scans underwent
quality control (15). Automatic segmentation results were
checked for errors and corrected if necessary by an experienced
observer blind to the subjects’ condition.
Lesion Load
Lesion load was measured on T2-FLAIR imaging scans, using
the lesion segmentation toolbox (LST) (16) of the statistical
parametric mapping (SPM) software for automatic lesion
detection, and was then manually corrected. Brain tissue volume,
normalized for subject head size, was estimated using SIENAX
(17), part of FSL (18).
Regional Tissue Volume Assessment
Regional tissue volume assessment was performed using
the region-based morphometry (RBM) module of the
Computational Analysis Toolbox (CAT12, Jena University
Hospital), an extension of SPM12 (Wellcome Department
of Cognitive Neurology). Data were prepared using default
preprocessing parameters, including brain segmentation (into
gray matter, white matter, and cerebral spinal fluid), and adding
surface and thickness estimation for region-of-interest (ROI)
analysis. Estimated ROI volume values were extracted for each
subject, using the LONI probabilistic brain atlas (LPBA40) (19)
and the results for all vision-related regions were compared
between the two subgroups (Supplementary Table 1).
Statistical Analysis
Mean values of all measures for MS-ALL were compared for
the two visits through paired 2-tailed t-tests to assess stability of
methods over a short duration. Mean values of all measures were
compared between MS-ON affected eyes (AE) and fellow eyes
(FE) through paired 2-tailed t-tests to assess the persistence of
ON-caused damage. Mean values of all measures were compared
between MS-nON eyes and the MS-ON AEs and FEs through
unpaired 2-tailed t-tests. Pearson correlation coefficients were
used to examine the associations between the VEP test and other
measures of the visual system.
Due to inter-eye latency correlations, linear mixed effects
models were built to test the relationship between the
various measures, group and VEP latency, with patient ID
as a random variable. Separate models were built between
families of test types (static visual tests—VA, LCLA; dynamic
visual tests—NFM, OFM; OCT measurements-macular volume,
pRNFL thickness) with VEP latency as dependent variable. All
significant parameters from the above models were fed to a
fourth model to explore interactions between eye subgroup
(AE, FE, non-averaged MS-nON eyes) and measures. Further
models were built for specific measures which have shown
significant interactions by group to test the interaction’s effect on
the measure.
Significance for all tests and correlations was assessed at
p < 0.05 level. Multiple comparisons correction was for
familywise error rate (FWE) using the Holm method. All
calculations were done using R-version 3.3.2 (R Foundation for
Statistical Computing, Vienna, Austria).
RESULTS
Subject Characteristics
MS-ALL group included 48 patients with progressive forms
of MS (18 progressive with relapses, 21 secondary-progressive,
9 primary-progressive, 20 females, average age 47.5 ± 9.5
years [mean ± SD]). Last treatments before inclusion included
fingolimod (21 patients), dimethyl fumarate (10), interferon β1a
(4), glatiramer acetate (4), natalizumab (3), teriflunomide (2),
rituximab (2), interferon β1b (1), and azathioprine (1). MS-ON
subgroup included 21 patients (8 females, 11 with right affected
eye, 8 with left affected eye, 2 with bilateral ON, mean time
from episode 16.8 ± 6.5 years). MS-nON subgroup included 27
patients (12 females). Visual assessments were made at two time
points, 66.1 ± 10.4 days apart. No significant differences were
found in EDSS, age, or in the BICAMS visuospatial memory
test (BVMTr) between the two subgroups (two-tailed t-test;
p = 0.95, p = 0.39, and p = 0.13, respectively). See Table 1 for
cohort characteristics.
Between-Visit Stability
All vision-related measures tested maintained consistency over
the two consecutive time-points in which measurements were
taken. T-test paired comparison was performed and no
significant differences were detected between visits in any of the
tested measures. Since no significant differences were detected,
further analyses are shown only for the first visit’s data.
Subgroup Visual Measures Comparison
To simplify analyses, differences between all measurements taken
for the right and left eyes of MS-nON patients were tested. As
no significant differences were found between eyes, the two eyes
of each MS-nON patient were averaged into a single value for
further comparisons against MS-ON AEs and FEs.
VEP latencies of all three eye subgroups were examined. The
latencies of 3 MS-ON AEs were excluded due to unsatisfactory
recording quality. With the exception of 2 MS-nON patients, all
patients in the MS-ALL group had abnormal latency values in
both eyes. However, significant differences were found between
MS-ON AEs and MS-ON FEs (paired t-test, N = 16; p = 0.014,
Figure 1A) as well as between MS-ON AEs and MS-nON eyes
(non-paired t-test, NMS−ON−AE = 16; NMS−nON = 27; p= 0.018,
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TABLE 1 | Study cohort characteristics.
MS-ALL MS-ON MS-nON
Subjects (n) 48 21 27
Sex (F/M) 20/28 8/13 12/15
Age (years ± SD; range) 47.5 ± 9.5 (26–67) 46.14 ± 8.53 (26–63) 48.56 ± 10.18 (30–67)
MS Form (PwR/SPMS/PPMS) 18/21/9 8/13/0 10/8/9
EDSS at start (median; range) 5.75 (3.5–6.5) 5.5 (4–6.5) 6 (3.5–6.5)
BVMTr (average ± SD; range) −0.03 ± 1.37 (−2.87 to 2.15) 0.31 ± 1.45 (−2.87 to 2.15) −0.29 ± 1.28 (−2.82 to 1.91)
Bilateral ON 2 2 N/A
AE (R/L) N/A 11/8 N/A
MS-ALL, full cohort; MS-ON, subjects with prior optic neuritis (ON); MS-nON, subjects without prior optic neuritis; PwR, progressive multiple sclerosis with relapses; SPMS, secondary-
progressive multiple sclerosis; PPMS, primary-progressive multiple sclerosis; EDSS, expanded disability status scale; BVMTr, Brief visuospatial memory test-revised; AE, affected eye;
R, right; L, left.
FIGURE 1 | VEP P100 latency differences between subgroups. (A) Paired t-test comparison of MS-ON fellow and affected eyes (n = 16) (B) Non-paired t-test
comparison of MS-nON eyes (n = 27), MS-ON fellow eyes (n = 19), and MS-ON affected eyes (n = 16). Error bars indicate SD. *Represents significance (p < 0.02).
Figure 1B). No significant differences were found between MS-
ON FEs andMS-nON eyes (non-paired t-test, NMS−ON−FE = 19;
NMS−nON = 27; p= 0.81, Figure 1B).
All other measures from the visual assessments also
underwent paired t-test comparisons between MS-ON AEs and
FEs and non-paired t-test comparisons between MS-nON eyes
and MS-ON AEs or FEs. In the AEs vs. FEs comparisons,
significant differences were found in most measures (VA, LCLA,
OFM/NFM, macular volume, pRNFL thickness, p < 0.03 for
all measures), confirming that the damage caused to the visual
pathways can still be discerned years following the acute episode.
The only exception was the HRR color test, though it was close
to significance (p = 0.057). In the MS-nON eyes vs. AEs or
FEs comparisons, on the other hand, no significant differences
were found in any of the measurements, though the differences
between MS-nON eyes and AEs showed a trend of worse scores
in the AEs.
Subgroup MRI Measures Comparison
To verify the similarity in disease load, brain volume, and
lesion count and load were compared between subgroups. No
significant differences were found in any of the measures.
Estimations of regional vision-related tissue volumes were also
compared between subgroups. No significant differences were
found (see Supplementary Table 1 for details regarding the
selected ROIs and results).
Motion Perception and VEP Latencies
Previous observations made by our group showed that dynamic
visual functions reflect myelination levels of the visual pathway,
as measured by VEP latencies (20). To examine whether these
observations hold true for patients even years after the acute
episode, the results of our motion perception tests (OFM/NFM)
were correlated to the VEP latencies of all eyes. Significant inverse
correlations were found between both motion perception tests
and the latencies of the AEs (N = 15; OFM: r = −0.701,
p = 0.004; MFM: r = −0.715, p = 0.003, Figure 2A) as well as
between the NFM test and the FE latency (N = 18, r = −0.48,
p = 0.042, Figure 2B), though this latter result did not survive
multiple comparison correction. Lack of correlation between
MS-ON FEs and OFM scores appear to stem from a single outlier
(when removed, r = 0.65, p = 0.005). No similar correlations
were observed in the MS-nON group (Figure 2C).
Since some of our cohort exhibited below-normal VA (<0.8,
no significant differences between MS-nON eyes and either MS-
ON AEs or FEs), to test whether the results were VA-dependent,
subjects in each eye subgroup were divided into “high” (≥0.8)
and “low” (<0.8) VA based on normal range definitions (21)
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FIGURE 2 | VEP P100 latency and NFM score correlations in subgroups. (A) MS-ON AE (p = 0.003); (B) MS-ON FE (p = 0.042); (C) MS-nON (p = 0.13).
and correlations were reanalyzed accordingly. Results revealed
that the correlations were driven by the “high” VA group in both
MS-ON AEs (n = 8; OFM: r = 0.84, p = 0.01; MFM: r = 0.93,
p = 0.0007, Figures 3A,B) and FEs (n = 11; OFM: trend only,
r = 0.54, p = 0.085; NFM: r = 0.84, p = 0.001, Figures 3C,D).
Similar division of subjects in the MS-nON group did not yield
the same results, with no correlation found in the “high” VA
group (not shown).
To examine whether the motion perception tests may also
be affected by axonal damage, test results were also correlated
to the pRNFL thickness and macular volume. No significant
correlations were found.
pRNFL Thickness and VEP Latencies
Whereas, the MS-ON cohort did not show any correlation
of the VEP latencies with the pRNFL thickness in either
eye (Figures 4A,B), such correlation was found for the MS-
nON latencies (r = −0.54, p = 0.006, Figure 4C), suggesting
a relationship between axonal damage and delay of signal
conduction in MS-nON patients, that is different from the
relationship observed in the MS-ON subgroup.
Mixed Effects Model
The mixed effects models showed that none of the static visual
tests were independently correlated with VEP latencies, whereas
NFM and pRNFL thickness both were significantly inversely
correlated to the latencies. A multivariate unified model with
eye subgroup (AE, FE, non-averaged MS-nON eyes), NFM, and
pRNFL thickness showed no significant difference in latency
between FEs and MS-nON eyes and that NFM was significantly
correlated with shorter latencies, whereas pRNFL thickness
was not (Table 2A). Since added interaction terms showed
significant interaction of NFM and pRNFL thickness with eye
group, separate models were built, correlating latencies with
these measures by eye group. This revealed that while NFM
was inversely correlated with the latencies in all subgroups, an
escalating effect exists, with significance rising fromMS-nON, to
FE, to AE (Table 2B). pRNFL thickness showed significant effect
in the MS-nON subgroup only (Table 2C).
DISCUSSION
Here, we have explored the visual system of progressive MS
patients and the effects of ON years after the acute episode and
found that despite the passage of time, previous ON episodes
still leave their mark in the patient’s visual system. This mark
is characterized by persistently prolonged VEP latencies in the
AEs of patients who have experienced prior ON in comparison
to both their FEs and the eyes of patients who have not had
ON. Additionally, even years after the acute episode, all visual
measures of the AE are notably reduced compared to the FE.
Motion perception, as a tool reflecting myelination levels along
the visual pathway, still showed its usefulness in progressive
MS. In the MS-nON eyes, axonal loss, as reflected by pRNFL
thinning, appears to explain the prolongation of conduction
velocities, unlike inMS-ON eyes, where demyelination appears to
be the main mechanism involved. Lastly, we have shown that the
visual measures evaluated in this study are replicable over short
durations, attesting their applicability as valid assessment tools in
therapeutic studies.
Residual Deficits in ON Affected Eyes
Years After the Episode
Previous studies, including the comprehensive North American
ON treatment trial (ONTT), have reported that most patients
suffering typical ON reach good visual recovery within a year of
onset (22), though persistent residual deficits may still remain,
encompassing the entire range of visual functions, including
VA and contrast sensitivity, color vision, stereopsis, and VEPs
(11). It has been suggested that incomplete recovery is the result
of persistent demyelination (20). Our results are in line with
those reporting residual deficits, showing them in almost all of
the tested functions, and further noting that when comparing
AE and FE in progressive MS patients, even in the presence
of accumulated disease load, it is still possible to discern the
AE from the FE. Furthermore, though there were no significant
differences found between the various visual measures of the
MS-nON eyes and the AEs, the general trend showed better
function of the MS-nON eyes compared to the AEs. Considering
the substantially unequal sizes of the subgroups, this non-
significance might be explained by the reduced power of the
non-paired compared to paired t-test.
Motion Perception as Myelination Marker
In Raz et al. (20), our group claimed that motion perception,
as shown by the OFM test scores, reflects myelination levels
of the optic nerve (20). The cohort in that study included
mostly CIS-ON patients and some early-stage MS patients.
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FIGURE 3 | VEP P100 latency and NFM score correlations in MS-ON eyes for “low” and “high” VA. Correlations are shown for MS-ON AE with “low” (A) and “high”
(B) VA (p = 0.999 and p = 0.0007, respectively) and for MS-ON FE with “low” (C) and “high” (D) VA (p = 0.613 and p = 0.001, respectively). Results shown for NFM
test only, but similar results are found for the OFM test.
FIGURE 4 | VEP P100 latency and pRNFL thickness correlations in subgroups. (A) MS-ON AE (p = 0.3); (B) MS-ON FE (p = 0.32); (C) MS-nON (p = 0.006).
Assessment was done over the first year following the acute
episode. Herein we show that this holds true in progressive
patients who underwent assessment many years following the
acute episode. It is known that the VEP latencies of ON
AEs commonly remain prolonged (23), reflecting incomplete
remyelination (20). In our current work we further emphasize the
persistent connection between conduction velocities and motion
perception, showing the applicability of the OFM/NFM tool
even in progressive patients. Though mixed effects models found
correlation between all eye subgroup latencies and NFM scores, a
significant escalation exists in correlation significance, suggesting
subtle demyelination as a global effect of the disease with greater
effects in lesioned sites. It should, however, be noted that the use
of the motion tools necessitates normal VA in subjects taking the
test and so might be limited in low VA subjects.
Contrary to the AE behavior in this cohort, which confirmed
our previous work, the FE behavior was decidedly different.
Briefly, in our previous early-stage cohort the relative
prolongation of the FE’s VEP latency did not correlate
with the ability to perform motion perception tests. It was
posited that the observed prolongations were caused by two
separate pathophysiological mechanisms. Whereas, in the AE
prolongation was derived from demyelination, in the FE it
was suggested that this was caused by compensatory cortical-
level mechanisms (24, 25). In the current cohort, however,
prolongation of the FE’s VEP latency did correlate with the
motion perception tests, suggesting a demyelinative effect rather
than cortical adaptive mechanism. Thus, whatever cortical
mechanisms may be involved in the early stages, here it is
possible that they have succumbed to the accumulation of
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TABLE 2 | Mixed effects model results.
Parameter Estimate [95% CI] p-value
(A) NFM and pRNFL–all subgroups
Subgroup FE 1.6 [−7.7, 10.8] 0.734
Subgroup AE 11.2 [1.5, 20.8] 0.024*
NFM −0.2 [−0.3, −0.1] 0.000*
pRNFL thickness −0.2 [−0.5, 0.1] 0.140
(B) NFM by subgroup
Subgroup FE 9.56 [−3.5, 22.6] 0.146
Subgroup AE 23.31 [11.3, 35.3] 0.000*
Subgroup MS-nON:NFM −0.12 [−0.2, 0] 0.025*
Subgroup FE:NFM −0.25 [−0.4, −0.1] 0.001*
Subgroup AE:NFM −0.34 [−0.5, −0.2] 0.000*
(C) pRNFL by subgroup
Subgroup FE −17.4 [−69.6, 34.8] 0.504
Subgroup AE −1.8 [−50.2, 46.6] 0.940
Subgroup MS-nON:pRNFL thickness −0.5 [−0.9, −0.1] 0.012*
Subgroup FE: pRNFL thickness −0.3 [−0.8, 0.2] 0.203
Subgroup AE: pRNFL thickness −0.4 [−0.8, 0.1] 0.117
FE, fellow eye; AE, affected eye; MS-nON, subjects without prior optic neuritis;
NFM, number-from-motion; pRNFL, peripapillary retinal nerve fiber layer.
*Represents significance.
disease. It has been previously shown in other neurodegenerative
diseases that compensatory mechanisms cannot withstand the
load of disease indefinitely and are more typical in the early
stages of disease (26).
And yet, how can demyelination of the FE be explained in the
absence of reported acute ON episode in that eye? The difference
in motion perception behavior between the MS-nON eyes and
FEs despite the similar disease stages and lesion load of the
two groups, points to a process unique to the FE. A possible
explanation, raised by Alshowaeir et al. in a recently published
study, is that of inflammation spillover from the AE (27). In
other words, demyelination of one optic nerve can affect the
fellow optic nerve. This proposed mechanism, however, needs to
be studied further. Notwithstanding, this suggests that the use
of FEs as controls for AEs in MS studies should be approached
more cautiously.
VEP Latency Prolongation Mechanisms
Accelerated pRNFL thinning (beyond the normal aging
processes) is known to occur in MS patients, even without
prior reported ON (7). The two suggested explanations are
the independent axonal loss component of the disease which
can occur also in the retina, and retro-chiasmal damage as
consequence of optic radiation lesions, a common finding in the
disease (28, 29). The pRNFL thickness in such cohorts was found
to correlate with both multifocal and full-field VEP latencies
(30, 31). In our cohort, we saw prolonged VEP latencies in all eye
subgroup, but the latencies of MS-nON eyes showed correlation
with pRNFL thickness whereas both MS-ON AEs and FEs did
not. It is possible that the results observed in the MS-nON
subgroup are indeed brought about by independent axonal
loss or retro-chiasmal mechanisms, and those observed in the
MS-ON subgroup have the additional element of demyelination
caused by direct damage to the optic nerve, overwhelming the
axonal effect.
Test Stability
Finally, the tests were performed roughly 2 months apart in
patients who have not undergone any therapeutic intervention or
demyelinative episodes in the interim. The consistency of results
obtained in these two assessments solidifies these measures as
reliable tools for patient assessment in clinical and research
setups. Additionally, the different information we gain by using
the various measures tested emphasizes the importance of
selecting the correct tool to answer the question studied, as we
have recently discussed (32).
LIMITATIONS AND FUTURE RESEARCH
This study was limited by the overall size of the group. In
particular, the size of the subgroups used was limited, as some
data could not be used in the MS-ON subgroup and due to the
inclusion of patients with bilateral past ON in the encompassing
study. This may have reduced the statistical power of the
analysis. Another influence on statistical power may stem from
the unequal sizes of the subgroups. An additional limitation
which should be noted is the predominance of male participants
in the study, despite the known female predominance in the
disease itself. We have no explanation for this bias, however, the
sex variable was included within the regression models and no
statistical significance effect of sex was found.
Future research into this question should follow a cohort of
MS patients with ON from early stages to later stages, attempting
to capture the point in which the putative adaptive mechanisms
fail under the onslaught of demyelination and disease load.
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